BioLineRx Ltd. (BLRX)

3.05
0.04 1.29
NASDAQ : Health Technology
Prev Close 3.09
Open 3.08
Day Low/High 2.95 / 3.08
52 Wk Low/High 0.29 / 27.60
Volume 25.03K
Avg Volume 379.20K
Exchange NASDAQ
Shares Outstanding 9.81M
Market Cap 31.58M
EPS -3.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioLineRx Announces Change In Ratio Of American Depositary Shares To Ordinary Shares

BioLineRx Announces Change In Ratio Of American Depositary Shares To Ordinary Shares

TEL AVIV, Israel, June 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Board of Directors has approved a change in the number of its ordinary...

BioLineRx To Present At The JMP Securities 2019 Life Sciences Conference

BioLineRx To Present At The JMP Securities 2019 Life Sciences Conference

TEL AVIV, Israel, June 13, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin, will present a company update at...

BioLineRx Reports First Quarter 2019 Financial Results And Provides Corporate Update

BioLineRx Reports First Quarter 2019 Financial Results And Provides Corporate Update

On track for Phase 2 data read-outs in pancreatic cancer and consolidation AML by year-end 2019

BioLineRx To Report First Quarter 2019 Results On May 14, 2019

BioLineRx To Report First Quarter 2019 Results On May 14, 2019

Management to hold a conference call at 10:00 a.m. EDT

BioLineRx Announces FDA Approval Of IND Application For AGI-134, A Novel Immunotherapy Anti-Cancer Vaccine For Solid Tumors

BioLineRx Announces FDA Approval Of IND Application For AGI-134, A Novel Immunotherapy Anti-Cancer Vaccine For Solid Tumors

- Phase 1/2a study ongoing in the UK and Israel, with sites in the US expected to join by H1 2020 -

BioLineRx Reports Year End 2018 Financial Results And Provides Corporate Update

BioLineRx Reports Year End 2018 Financial Results And Provides Corporate Update

BL-8040 and AGI-134 oncology programs progressing, with multiple data read-outs expected in the next 12 months

BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial For BL-8040 In Multiple Myeloma Patients

BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial For BL-8040 In Multiple Myeloma Patients

Results presented as oral presentation at 45th Annual Meeting of European Society for Blood and Marrow Transplantation

BioLineRx To Report Annual 2018 Results On March 28, 2019

BioLineRx To Report Annual 2018 Results On March 28, 2019

Management to hold a conference call at 10:00 a.m. EDT

BioLineRx To Present At The 29th Annual Oppenheimer Healthcare Conference

BioLineRx To Present At The 29th Annual Oppenheimer Healthcare Conference

TEL AVIV, Israel, March 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin, will present a company update at...

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

BioLineRx (BLRX) signed a licensing agreement with two Israeli companies to allow the development of a drug that treats liver failure conditions.

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

7 Stocks Under $10 Making Big Moves

7 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment

BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment

BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions...

BioLineRx Establishes Oncology Scientific Advisory Board

BioLineRx Establishes Oncology Scientific Advisory Board

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific...

BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015

BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast...

BioLineRx To Present At The LD Micro Main Event

BioLineRx To Present At The LD Micro Main Event

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Reports Third Quarter 2015 Financial Results

BioLineRx Reports Third Quarter 2015 Financial Results

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third...

BioLineRx To Report Third Quarter 2015 Results On November 16, 2015

BioLineRx To Report Third Quarter 2015 Results On November 16, 2015

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited...

BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML

BioLineRx Announces Positive Clinical Results From First Part Of Phase 2 Trial In R/r AML

BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive results from the dose...

BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Submitted For CE Mark Registration

BioLineRx's Novel Treatment For Non-Surgical Removal Of Skin Lesions Submitted For CE Mark Registration

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Omega Pharma,...

BioLineRx To Present At The 17th Annual Rodman & Renshaw Global Investment Conference In New York

BioLineRx To Present At The 17th Annual Rodman & Renshaw Global Investment Conference In New York

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Reports Second Quarter 2015 Financial Results

BioLineRx Reports Second Quarter 2015 Financial Results

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the...

BioLineRx Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment

BioLineRx Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a Phase 2b...

BioLineRx To Report Second Quarter 2015 Results On August 20, 2015

BioLineRx To Report Second Quarter 2015 Results On August 20, 2015

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its...

BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results

BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results

BioLineRx (BLRX) shares are down by almost 20% after the company confirmed weak results from its placebo-controlled heart disease treatment tests.

BioLineRx Announces Top-Line Results From Bellerophon's PRESERVATION I Clinical Trial For Bioabsorbable Cardiac Matrix (BL-1040)

BioLineRx Announces Top-Line Results From Bellerophon's PRESERVATION I Clinical Trial For Bioabsorbable Cardiac Matrix (BL-1040)

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Bellerophon,...

Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation

Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation

Bioline RX (BLRX) shares are rising as it presents in the Celiac Disease Symposium in Prague this week as well as coverage initiation by analysts at JPMorgan.

BioLineRx To Present Successful Results Of Phase 1/2 Study For Novel Celiac Treatment At International Celiac Disease Symposium

BioLineRx To Present Successful Results Of Phase 1/2 Study For Novel Celiac Treatment At International Celiac Disease Symposium

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will present positive...